

Date	Time	Topic	Speaker
Sept 4th	10:00-12:00	Registration	
	13:30-13:40	Opening Remarks	Haisheng Wang General Manager (China), Mybiogate Inc.
	13:40-14:10	Novel Drugs To Enter China Under Cfda Reform: Opportunities And Challenges	Haisheng Wang General Manager (China), Mybiogate Inc.
	14:10-14:35	Current Status And Outlook Of Immunotherapy In China	Qiang Lu Chairman, Genfleet Pharmaceutical
	14:35-15:00	New Drug Innovations In China And Its Unique Opportunities For Investment And Partnering	Lynn Yang Managing Director, Sequoia Capital China
	15:00-15:25	Chinese Big Pharma's Strategy In Drug Development	Ai-min Hui (Tbd) CMO, Fosun Pharma
	15:25-15:50	Livzon Mabpharm: Company Introduction And Global Development Strategy	John Chen Director Of Business Development, Livzon Mabpharm, Inc
	15:50-16:10	Break	
	16:10-16:55	Panel Discussion 1: Rise Of Chinese Healthcare Market	Rebecca Robbins (Moderator) Business Reporter, STAT News
			Anjiang (Vincent) Liu Senior Advisor, Fosun Pharma
			Yuanhua Ding Head Of External R&D Innovation - Asia Pfizer Worldwide Research & Development
			Noel Goddard Accelerate Ny Seed Fund, Principal
	16:55-17:40	Panel Discussion 2: China Focus: Cross-border Investment And Collaboration	Douglas Thien (Moderator) Immunomic Therapeutics China Strategic Advisor
			Kim Nearing Cedrus Group, Managing Director
Chong Xu F-prime Capital Partners Senior Associate			
Yan Zhang Investment Director, Cowin Capital			
Bob Ai SVP, The Trout Group			
Sept 5th	8:00-9:30	1-to-1 Meetings	
	9:30-9:45	Showcase: Industry Research Report Of Pd-(L)1 Combo Therapies	Ginger Ding Director Of Research, Mybiogate Inc.
	9:45-10:05	Building Next Generation Biologics Using Expended Genetic Code	Feng Tian Chief Scientific Officer, ambrx
	10:05-10:25	Bispecific Antibodies For Cancer Immunotherapy: Design Strategies And Development Challenges	Jinming Gu Abpro Labs Head Of Biologics Development
	10:25-11:00	Panel Discussion 3: Current Status And Outlook Of I.O. Drug Development	Gu Jinming (Moderator) Head Of Biologics Development Abpro Labs
			Wenru Song Co-founder&president Kira Pharmaceuticals
			Patrick Liu Executive Vice President Sincere Pharmaceutical Group
			Jian Irish Global Head Of Manufacturing Kite Pharma
	11:00-11:20	Neuroscience Drug Discovery: Current Frontiers And Future Perspectives	
	11:20-12:00	Company Pitch	Phasebio / Immunomic Therapeutics / QR Pharma
	12:00-13:30	Lunch Break And 1-to-1 Meetings	
	13:30-13:45	Showcase: Industry Research Report Of Car-t/tcr-t	Ginger Ding Director Of Research, Mybiogate Inc.
	13:45-14:05	Lymphocyte Adoptive Cell Therapy In Oncology: Challenges And Opportunities	Miguel Forte CEO, zelluna Immunotherapy
	14:05-14:25	Development Of Allogeneic, Off-the-shelf Car-t Treatments For Hematological Malignancies And Solid Tumors	Stefanos Theoharis SVP Corporate Development And Partnering Cell Medica
14:25-14:45	Car-t Cell Therapeutics For The Treatment Of Solid Tumor	Zonghai Li CEO&CSO, Carsgen Therapeutics	
14:45-15:30	Panel Discussion 4: Adoptive Cell Transfer: Innovations And Global Collaborations	Miguel Forte CEO (Moderator) Zelluna Immunotherapy	
		Stefanos Theoharis Cell Medica, SVP Corporate Development And Partnering	
		Zonghai Li CEO&CSO, Carsgen Therapeutics	
		Zhinan Xia Founder And CSO Abimmune Bio	
		John Lu CEO, Vcanbio Center For Translational Biotechnology	
15:30-16:00	Break		
16:00-16:10	Showcase: Synageva's Experience In Developing Kanuma's Orphan Disease Drugs	Zhinan Xia Founder And CSO Abimmune Bio	
16:10-16:50	Company Pitch	Neuexcell Therapeutics / Ayass Bioscience LLC	
16:50-18:00	1-to-1 Meetings		
Sept 6th	8:00-17:00	1-to-1 Meetings	